ExoLuminate Study for Early Detection of Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05625529|
Recruitment Status : Not yet recruiting
First Posted : November 23, 2022
Last Update Posted : December 8, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in those patients that are at an elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC).
Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, a family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, a personal or family history of pancreatitis, or new onset diabetes after age 50.
The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.
|Condition or disease|
|Pancreas Cancer Exosomes Extracellular Vesicles Pancreatic Neoplasms|
Biological Dynamics, Inc. has developed a non-invasive blood test ("liquid biopsy" ) that can identify early-stage disease with high sensitivity and specificity. The proprietary ExoVerita™ assay uses alternating current electric (ACE) field to isolate extracellular vesicles (EVs) for differentiated multiomics applications and includes an optimized machine learning algorithm to identify a panel of EV-bound protein biomarkers in patient's plasma in order to detect PDAC at earlier stages.
ExoLuminate is a prospective, multi-center, observational registry study designed to evaluate the non-inferiority of the performance of the ExoVerita™ assay in detecting pancreatic ductal adenocarcinoma (PDAC) in high-risk or clinically-suspicious populations in comparison to standard-of-care methods.
The study is planned to recruit a minimum of 1000 U.S. adults over 2-years (with a 1-year follow-up for data collection).
The test will be ordered through providers. Eligible subjects will be evaluated using the ExoVerita™ assay through blood donation(s) at specified time intervals. Overall, this study poses minimal risk to subject.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||1000 participants|
|Target Follow-Up Duration:||1 Year|
|Official Title:||Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients|
|Estimated Study Start Date :||December 1, 2022|
|Estimated Primary Completion Date :||January 1, 2026|
|Estimated Study Completion Date :||January 1, 2027|
Cohort 1: High-Risk Population
Cohort 2: Clinically-suspicious PDAC or Pathologically-confirmed
- Clinical performance of ExoVerita™ assay [ Time Frame: 24 months or until diagnostic resolution ]Specificity
- Clinical performance of ExoVerita™ assay [ Time Frame: 24 months or until diagnostic resolution ]Sensitivity
- Stage Shift [ Time Frame: 24 months or until diagnostic resolution ]Evaluation of stage distribution (SEER) at diagnosis
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
Cohort 1 -
- IPMN lesions, any age.
- Family member(s) who have at least one FDR affected by PDAC, Age ≥50 (or 10 years earlier than youngest afflicted relative)
- STK11 (Peutz-Jeghers syndrome), any age.
- CDKN2A, p16 (Familial atypical multiple mole and melanoma; FAMMM), any age.
- BRCA1, BRCA2, ATM, PALB2, ≥45 (or 10 years earlier than youngest afflicted relative)
- MLH1, MSH2, MSH6, PMS2, EPCAM, TP53 (HNPCC), Age ≥50 (or 10 years earlier than youngest afflicted relative)
- Hereditary Pancreatitis with confirmed PRSS1. Age ≥40
- Acute, Chronic, or Hereditary Pancreatitis, any age.
- New-onset diabetes, age ≥50
Cohort 2 -
- Clinical findings suspicious for early stage PDAC OR
- Biopsy-proven, clinical stage I-IV PDAC
- ≥18 years old
- Cohort 1 or Cohort 2
- Capable of giving informed consent
- Able to provide a blood sample
- Tested for the presence of deleterious germline mutations associated with PDAC or willing to provide samples for germline genetic analysis.
- < 18 years old
- Undergoing any active treatment from of an active cancer diagnosis (except for skin malignancies).
- History of fainting or other adverse effects when blood is drawn.
- Unwilling to provide germline mutation information or samples for germline genetic analysis
- Any condition that, in the opinion of the investigator, should preclude enrollment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05625529
|Contact: Harmeet Dhani, MD, M.Scemail@example.com|
|Principal Investigator:||Harmeet Dhani, MD, M.Sc||Biological Dynamics|
|Responsible Party:||Harmeet Dhani, Medical Director, Biological Dynamics|
|Other Study ID Numbers:||
|First Posted:||November 23, 2022 Key Record Dates|
|Last Update Posted:||December 8, 2022|
|Last Verified:||December 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Endocrine System Diseases